

# Lipase-catalyzed Kinetic Resolution of (±)-*trans*- and *cis*-2-Azidocycloalkanols

Ei'ichi AMI and Hiroshi OHRUI<sup>†</sup>

Division of Life Science, Graduate School of Agricultural Science, Tohoku University,  
Tsutsumidori-Amamiyamachi 1-1, Aoba-ku, Sendai, 981-8555, Japan

Received July 9, 1999; Accepted August 17, 1999

The lipase-catalyzed kinetic resolution of *trans*- and *cis*-2-azidocycloalkanols and the preparation of enantiomerically pure *trans*- and *cis*-2-aminocycloalkanols are described.

Four kinds of lipases were screened for the acetylation of *trans*- and *cis*-2-azidocycloalkanols. Among them, *Pseudomonas* sp. lipases (lipase PS and lipase AK, Amamo Pharmaceutical Co.) showed the highest enantioselectivity. These products were converted to the corresponding 2-aminocycloalkanols to determine their enantiomeric excess (*ee*) and absolute configurations by HPLC and CD analyses, using (*S*)-TBMB carboxylic acid [(*S*)-2-*tert*-butyl-2-methyl-1,3-benzodioxole-4-carboxylic acid] as the chiral conversion reagent. The results of the CD analysis proved *N,O*-bis-(*S*)-TBMB carboxylated *cis*-2-aminocycloalkanols to adopt a predominantly *N*-equatorial conformation.

The partially resolved *trans*- and *cis*-2-aminocycloalkanols, except for *trans*-2-aminocyclopentanol, were recrystallized from ethyl acetate to give enantiomerically pure forms.

**Key words:** lipase-catalyzed kinetic resolution; 2-azidocycloalkanols; 2-aminocycloalkanols; CD detection; (*S*)-TBMB carboxylic acid

Chiral 2-amino alkanols have received wide attention in recent years for their diverse applications as versatile starting materials for constructing bioactive compounds such as antibiotics,<sup>1)</sup> alkaloids,<sup>2)</sup> and enzyme inhibitors,<sup>3)</sup> as chiral resolving reagents,<sup>4)</sup> and as chiral auxiliaries for asymmetric syntheses.<sup>5)</sup>

Despite the many synthetic methods for optically pure *trans*- and *cis*-2-aminocycloalkanols that have been reported,<sup>6)</sup> it is still challenging to develop a new practical preparative method for these compounds. The most sophisticated chemical method for preparing *trans*-2-aminocycloanol so far would be the one reported by Overman and Sugai in 1985,<sup>7)</sup> although, their method is not suited for practical preparation in respect of convenience and mass production. Moreover, an efficient chiral synthesis of *cis*-2-aminocycloalkanols has not been reported.

Since 2-aminocycloalkanols could be easily prepared from 2-azidocycloalkanols, it was considered that the lipase-catalyzed resolution<sup>8)</sup> of racemic *trans*- and *cis*-2-azidocycloalkanols would be a practical method for mass preparation of enantiomerically pure *trans*- and *cis*-2-aminocycloalkanols.

We report here the enzymatic optical resolution of *trans*- and *cis*-2-azidocycloalkanols [(±)-*trans*-1a~c and (±)-*cis*-1a, b] and the preparation of optically pure *trans*- and *cis*-2-aminocycloalkanols from the resolved 2-azidocycloalkanols.

## Results and Discussion


The *trans*-substrates [(±)-*trans*-1a~c] were prepared from the corresponding cycloalkenes by oxidation with *m*-chloroperbenzoic acid (*m*-CPBA), and then by opening the epoxide with sodium azide to give *trans*-2-azidocycloalkanols. The *cis*-substrates [(±)-*cis*-1a, b] were prepared from the corresponding (±)-*trans*-1a and 1b by using Nakata's inversion method for secondary alcohols.<sup>9)</sup> (Scheme 1)

The lipase-catalyzed acetylation of (±)-*trans*-1a~c and (±)-*cis*-1a, b was carried out in vinyl acetate, which was also used as the acetylating reagent, for 20 hours [(±)-*trans*-1a~c], and for 4–10 hours [(±)-*cis*-1a, b] at 40°C with four kinds of lipases (Lipase PS and Lipase AK each derived from *Pseudomonas* sp, Lipase AY30 derived from *Candida rugosa*, and Lipase AP12 derived from *Aspergillus niger*). (Scheme 2)

The results are summarized in Tables 1 and 2.


The absolute configurations of the predominant isomers of all the *trans*-acetates (2a~c) and of the unreacted *trans*-2-azidocycloalkanols (1a~c) were determined by a CD analysis of the corresponding 2-aminocycloalkanols after *N,O*-bis-(*S*)-TBMB carboxylation. The *ee* values for the products were determined by HPLC of the *N,O*-bis-(*S*)-TBMB derivatives.

*trans*-Acetates 2a~c were isolated by column chromatography and were deacetylated. The resulting *trans*-2-azidocycloalkanols and the remaining substrates were



**Scheme 1.** Preparation of 2-Azidocycloalkanols (±)-*trans*-1a~c and (±)-*cis*-1a, b.

<sup>†</sup> To whom correspondence should be addressed. Fax: 81-22-717-8806; E-mail: ohroi@biochem.tohoku.ac.jp



**Scheme 2.** Kinetic Resolution of ( $\pm$ )-*trans*-1a~c and ( $\pm$ )-*cis*-1a, b, Structure of (*S*)-TBMB Carboxylic Acid (**4**), and Chiral Conversion of *trans*-3a~c for the HPLC and CD Analyses.

**Table 1.** Kinetic Resolution of the ( $\pm$ )-*trans*-2-Azidocycloalkanols [( $\pm$ )-*trans*-1a~c]

Entry	Substrate	Lipase	Time (hr)	(1 <i>R</i> , 2 <i>R</i> )-2		(1 <i>S</i> , 2 <i>S</i> )-1		E
				Yield (%)	%ee	Yield (%)	%ee	
1	<i>trans</i> -1a	Lipase PS	20	57	75.8	35	>99.9	
2	<i>trans</i> -1a	Lipase AK	20	46	90.0	43	97.9	87
3	<i>trans</i> -1a	Lipase AY30	20	68	0.54	30	39.4	1
4	<i>trans</i> -1a	Lipase AP12	20	32	77.6	62	48.4	13
5	<i>trans</i> -1b	Lipase PS	20	45	98.1	42	98.7	522
6	<i>trans</i> -1b	Lipase AK	20	44	96.0	40	98.9	253
7	<i>trans</i> -1b	Lipase AY30	20	24	92.3	65	50.3	41
8	<i>trans</i> -1b	Lipase AP12	20	7	95.7	78	24.5	58
9	<i>trans</i> -1c	Lipase PS	20	41	98.5	46	72.7	288
10	<i>trans</i> -1c	Lipase AK	20	45	98.6	41	99.4	815
11	<i>trans</i> -1c	Lipase AY30	20	32	86.0	51	54.2	23
12	<i>trans</i> -1c	Lipase AP12	20	5	87.4	79	12.6	17

**Table 2.** Kinetic Resolution of the ( $\pm$ )-*cis*-2-Azidocycloalkanols [( $\pm$ )-*cis*-1a, b]

Entry	Substrate	Lipase	Time (hr)	(1 <i>R</i> , 2 <i>S</i> )-2		(1 <i>S</i> , 2 <i>R</i> )-1		E
				Yield (%)	%ee	Yield (%)	%ee	
1	<i>cis</i> -1a	Lipase PS	4	42	92.2	47	79.4	60
2	<i>cis</i> -1a	Lipase PS	12	49	87.2	36	88	42
3	<i>cis</i> -1a	Lipase AK	6	48	95.1	48	99	209
4	<i>cis</i> -1a	Lipase AK	12	48	87.3	43	99.3	82
5	<i>cis</i> -1b	Lipase PS	10	47	79.6	47	76.8	20
6	<i>cis</i> -1b	Lipase AK	10	47	98.8	48	95.2	622

submitted to a Staudinger azide reduction<sup>10)</sup> to give the corresponding *trans*-2-aminocycloalkanols (**3a~c**), which were then labelled with (*S*)-TBMB carboxylic acid<sup>11)</sup> (**4**) in the presence of water-soluble carbodiimide (WSC) to give the *N,O*-bis-(*S*)-TBMB carboxylated derivatives (**5a~c**), respectively, for submission to the

HPLC and CD analyses.

The fluorescence-detected HPLC chromatograms of the *N,O*-bis-(*S*)-TBMB-carboxylated *trans*-2-aminocycloalkanols (**5a~c**) derived from racemic *trans*-2-aminocycloalcohols are shown in Fig. 1. As can be seen, all the chromatograms show 1:1 peaks of *trans*-5a~c to

indicate that no chiral discrimination during conversion had taken place. Thus, the optical purity of the 2-azidocycloalkanols could be determined by the HPLC method.

All the *N,O*-bis-(*S*)-TBMB-carboxyl derivatives of enantiomers of the *trans*-2-aminocycloalkanols gave symmetrical exciton CD spectra to indicate their absolute configurations. The CD spectra of (1*R*, 2*R*)- and (1*S*, 2*S*)-**5a** ~ **c** are shown in Fig. 2.

These results enabled the absolute configuration eluates of the first eluates from HPLC to be determined as




Fig. 1. HPLC Chromatograms of (±)-2-Aminocycloalkanol Derivatives *trans*-**5a** ~ **c**.

Conditions: mobile phase, *n*-hexane:THF=20:1; flow rate, 1 ml/min; column, TSK-GEL (TOSOH).

1*S*, 2*S*. The second eluates were determined to be of 1*R*, 2*R* configuration.

The absolute configurations of the main components of the *cis*-acetates (**2a**, **b**) and of the unreacted *cis*-2-azidocycloalkanols (**1a**, **b**) were determined to be 1*R*, 2*S* and 1*S*, 2*R*, respectively, by comparing with the HPLC chromatograms of *trans*-**5a** and **5b** after Walden-inversion of the secondary alcohol, reduction of the azido group, and conversion with **4**. (Scheme 3)


The CD spectra of the *N,O*-bis-(*S*)-TBMB-carboxylated *cis*-2-aminocycloalkanols (**5a**, **b**) were of the exciton type to show that *N,O*-bis-(*S*)-TBMB-carboxylated (1*R*, 2*S*)-**5a**, **b** exist mainly in a clockwise conformation, and the (1*S*, 2*R*)-isomers in an *anti*-clockwise one. (Fig. 3)

These results indicate that the equatorial preference of the TBMB-carboxylated amino group was stronger than that of the TBMB-carboxylated hydroxy group.

In general, the hydroxy group in an (*R*) configuration was preferentially acetylated by the lipases, except for the acetylation of *trans*-**1a** with Lipase AY30. Compared with *trans*-**1b** and *trans*-**1c**, *trans*-**1a** was more easily acetylated with any of the lipases. Fortunately, Lipase PS gave enantiomerically pure (1*S*, 2*S*)-2-azidocyclopentanol **3a**. Although Lipase AY30 and AP12 were not suitable for the kinetic resolution, the *Pseudomonas* sp. lipases showed sufficient reactivity and enantioselectivity.

The 2-aminocycloalkanols, except for *trans*-2-aminocyclopentanol **3a**, could be crystallized. These chiral 2-aminocycloalkanols were recrystallized from ethyl acetate to give enantiomerically pure compounds. The total yield of each enantiomerically pure 2-aminocycloalkanol starting from the corresponding 2-azidocycloalkanol was 22–29%.

In conclusion, we have demonstrated lipase-catalyzed



Scheme 3. Conversion of *cis*-**1a**, **b** to *trans*-**1a**, **b**.





Fig. 2. CD Spectra for *trans*-**5a** ~ **c**.

Fig. 3. CD Spectra for *cis*-5a, b.

kinetic resolution to be a powerful tool for obtaining optically pure *trans*- and *cis*-2-aminocycloalkanols. We also found *N,O*-bis-(*S*)-TBMB carboxylated *cis*-2-aminocycloalkanols [(1*R*, 2*S*)- and (1*S*, 2*R*)-5a, b] gave exciton-coupled CD spectra.

The prepared 2-aminocycloalcohols could be used as the backbone for fluorescent chiral conversion reagents to discriminate remote chirality.<sup>12)</sup> Syntheses of the chiral conversion reagents from these 2-aminocycloalcohols are underway.

## Experimental

Melting point (mp) data were recorded with Yanaco melting point apparatus and are uncorrected. <sup>1</sup>H-NMR spectra were recorded with a Varian Gemini 2000/300 instrument at 21–23°C in CDCl<sub>3</sub> with Me<sub>4</sub>Si as an internal standard. MS spectra were obtained with a JEOL JMS-DX 303HF instrument, and IR spectra were measured with Nicolet Impact 410 apparatus. [α]<sub>D</sub> values were measured with a JASCO DIP-4 spectrometer at 20°C. The HPLC system for measuring the fluorescence intensity consisted of a JASCO PU-980 liquid chromatographic pump, a 77251 injector with a 20-μl sample loop (Rheodyne), a TSK-GEL (TOSOH) separation column, a Toyo Soda FS-8000 fluorescence detector and Jasco-807IT recorder. CD spectra were obtained with a JASCO J-720 spectrometer, and silica gel column chromatography was conducted on Merck silica gel (Art. 7734).

(±)-*trans*-2-azidocyclopentanol [(±)-*trans*-1a]. To a solution of *m*-CPBA (14.00 g, 81.13 mmol) in CHCl<sub>3</sub> (300 ml) was added cyclopentene (5.00 g, 73.46 mmol). The reaction mixture was stirred for 12 hours at between 0°C and room temperature, quenched by adding sat. aq. NH<sub>4</sub>Cl and then extracted with ether (300 ml). The combined extracts were dried with MgSO<sub>4</sub>, filtered, and

concentrated *in vacuo*. The residue (cyclohexene oxide) was submitted to the next process. To a solution of NaN<sub>3</sub> (10.00 g, 153.82 mmol) and NH<sub>4</sub>Cl (5.00 g, 93.48 mmol) in DMF-H<sub>2</sub>O (100 ml, 10:1, v/v) was added this residue. The mixture was stirred and refluxed for 3 hours, then extracted with ether (300 ml), dried with MgSO<sub>4</sub>, filtered, concentrated *in vacuo*, and purified by column chromatography (hexane-ethyl acetate=10:1) to provide (±)-*trans*-1a (8.21 g, 64.64 mmol, 88% yield in two steps) as an oil. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 4.07 (m, 1H), 3.70 (m, 1H), 2.52 (s, 1H, -OH), 2.14–1.94 (m, 2H), 1.87–1.53 (m, 4H). HRMS *m/z*: calcd. for C<sub>5</sub>H<sub>9</sub>ON<sub>3</sub>, 127.0745 (M<sup>+</sup>); found, 127.0748 (M<sup>+</sup>) (EI<sup>+</sup>). IR (KBr disk) ν<sub>max</sub> cm<sup>-1</sup>: 3356 (-OH), 2100 (azide). *Anal.* Calcd. for C<sub>5</sub>H<sub>9</sub>ON<sub>3</sub>: C, 47.22; H, 7.14; N, 33.06%. Found: C, 47.30; H, 7.15; N, 33.10%.

(±)-*trans*-2-azidocyclohexanol [(±)-*trans*-1b]. To a solution of NaN<sub>3</sub> (7.36 g, 113.18 mmol) and NH<sub>4</sub>Cl (4.04 g, 75.45 mmol) in DMF-H<sub>2</sub>O (100 ml, 10:1, v/v) was added commercially available cyclohexene oxide (7.40 g, 75.45 mmol). The mixture was stirred and refluxed for 3 hours, then extracted with ether (300 ml), dried with MgSO<sub>4</sub>, filtered, concentrated *in vacuo*, and purified by column chromatography (hexane-ethyl acetate=5:1) to provide (±)-*trans*-1b (10.20 g, 72.29 mmol, 96% yield) as an oil. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ (ppm): 3.39 (m, 1H), 3.19 (m, 1H), 2.44 (dd, 1H, -OH, *J*=3.2 Hz), 2.04 (m, 2H), 1.75 (m, 2H), 1.31 (m, 4H). HRMS *m/z*: calcd. for C<sub>6</sub>H<sub>11</sub>ON<sub>3</sub>, 142.1019 (M<sup>+</sup> + H); found, 142.0990 (M<sup>+</sup> + H) (FAB<sup>+</sup>). IR (KBr disk) ν<sub>max</sub> cm<sup>-1</sup>: 3370 (-OH), 2100 (azide). *Anal.* Calcd. for C<sub>6</sub>H<sub>11</sub>ON<sub>3</sub>: C, 51.03; H, 7.86; N, 29.77%. Found: C, 51.06; H, 7.92; N, 29.66%.

(±)-*trans*-2-azidocycloheptanol [(±)-*trans*-1c]. (±)-*trans*-1c was prepared from cycloheptene with a 90%

yield in two steps according to the procedure described for (±)-*trans*-**1a** and obtained as an oil. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm): 3.52 (m, 1H), 3.70 (m, 1H), 2.31 (s, 1H, -OH), 1.98–1.84 (m, 2H), 1.79–1.40 (m, 8H). HRMS *m/z*: calcd. for C<sub>7</sub>H<sub>13</sub>ON<sub>3</sub>, 155.1058 (M<sup>+</sup>); found 155.1062 (M<sup>+</sup>) (EI<sup>+</sup>). IR (KBr disk) ν<sub>max</sub> cm<sup>-1</sup>: 3384 (-OH), 2100 (azide). *Anal.* Calcd. for C<sub>7</sub>H<sub>13</sub>ON<sub>3</sub>: C, 54.16; H, 8.45; N, 27.08%. Found: C, 54.10; H, 8.42; N, 27.10%.

(±)-*cis*-2-azidocyclopentanol [(±)-*cis*-**1a**]. To a solution of (±)-*trans*-**1a** (3.15 g, 24.79 mmol) in pyridine (100 ml) was added chloromethanesulfonyl chloride (6.00 g, 40.27 mmol). The reaction mixture was stirred for 1 hour at 0°C and then extracted with ether. The combined extracts were dried with MgSO<sub>4</sub>, filtered, concentrated *in vacuo*, and purified by column chromatography (hexane-ethyl acetate=10:1) to provide chloromethanesulfonate (5.10 g, 21.29 mmol, 86% yield). To a solution of cesium acetate (1.20 g, 6.25 mmol) and 18-crown-6 (1.20 g, 4.54 mmol) in toluene (100 ml) was added this chloromethanesulfonate (1.00 g, 4.18 mmol). The mixture was stirred and refluxed for 2 hours, then extracted with ether (100 ml), dried with MgSO<sub>4</sub>, filtered, concentrated *in vacuo*, and purified by column chromatography (hexane-ethyl acetate=10:1) to provide (±)-*trans*-2-azidocyclopentyl acetate. To a solution of NaOMe (50 mg) and MeOH (100 ml) was added this product. The reaction mixture was stirred for 2 hours at room temperature, then extracted with ether (100 ml), dried with MgSO<sub>4</sub>, filtered, concentrated *in vacuo*, and purified by column chromatography (hexane-ethyl acetate=10:1) to provide (±)-*cis*-**1a** (0.38 g, 3.01 mmol, 72% yield in two steps) as an oil. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ (ppm): 4.15 (m, 1H), 3.79 (m, 1H), 2.11 (s, 1H, -OH), 1.93 (m, 4H), 1.67 (m, 2H). HRMS *m/z*: calcd. for C<sub>5</sub>H<sub>9</sub>ON<sub>3</sub>, 127.0745 (M<sup>+</sup>); found, 127.0746 (M<sup>+</sup>) (EI<sup>+</sup>). IR (KBr disk) ν<sub>max</sub> cm<sup>-1</sup>: 3344 (-OH), 2100 (azide). *Anal.* Calcd. for C<sub>5</sub>H<sub>9</sub>ON<sub>3</sub>: C, 47.22; H, 7.14; N, 33.06%. Found: C, 47.28; H, 7.16; N, 33.10%.

(±)-*cis*-2-azidocyclohexanol [(±)-*cis*-**1b**]. (±)-*cis*-**1b** was prepared from (±)-*trans*-**1b** in a 76% yield in three steps according to the procedure described for (±)-*cis*-**1a** and obtained as an oil. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ (ppm): 3.81 (ddd, 1H, *J*=3.0 Hz), 3.67 (ddd, 1H, *J*=3.0 Hz), 2.18 (s, 1H, -OH), 1.90 (m, 2H), 1.67 (m, 4H), 1.37 (m, 2H). HRMS *m/z*: calcd. for C<sub>6</sub>H<sub>11</sub>ON<sub>3</sub>, 141.0901 (M<sup>+</sup>); found, 141.0903 (M<sup>+</sup>) (EI<sup>+</sup>). IR (KBr disk) ν<sub>max</sub> cm<sup>-1</sup>: 3375 (-OH), 2100 (azide). *Anal.* Calcd. for C<sub>6</sub>H<sub>11</sub>ON<sub>3</sub>: C, 51.03; H, 7.86; N, 29.77%. Found: C, 51.07; H, 7.82; N, 29.71%.

*Enantioselective acetylation of (±)-trans-1a~c and (±)-cis-1a, b with lipases.* *General method:* To a solution of (±)-*trans*-**1a** (1.50 g, 11.80 mmol) and vinyl acetate (30 ml) was added Lipase PS (1.00 g), and the reaction mixture was stirred for 20 hours at 40°C. The mixture was then filtered through Celite, and the filtrate was concentrated *in vacuo*. The crude product obtained was chromatographed on silica gel. Elution with hexa-

ne-ethyl acetate (10:1) gave acetate (1*R*, 2*R*)-**2a** (1.13 g, 6.68 mmol, 57% yield) and remaining substrate (1*S*, 2*S*)-**1a** (0.53 g, 4.17 mmol, 35% yield). (±)-*trans*-**1a** (10.80 g, 84.99 mmol) with Lipase AK gave (1*R*, 2*R*)-**2a** (6.68 g, 39.51 mmol, 46% yield) and (1*S*, 2*S*)-**1a** (4.64 g, 36.51 mmol, 43% yield). (±)-*trans*-**1a** (1.15 g, 9.05 mmol) with Lipase AY30 gave (1*R*, 2*R*)-**2a** (1.04 g, 6.15 mmol, 68% yield) and (1*S*, 2*S*)-**1a** (0.35 g, 2.75 mmol, 30% yield). (±)-*trans*-**1a** (1.32 g, 10.39 mmol) with Lipase AP12 gave (1*R*, 2*R*)-**2a** (0.57 g, 3.37 mmol, 32% yield) and (1*S*, 2*S*)-**1a** (0.82 g, 6.45 mmol, 62% yield). (±)-*trans*-**1b** (5.30 g, 37.56 mmol) with Lipase PS gave (1*R*, 2*R*)-**2b** (3.12 g, 17.04 mmol, 45% yield) and (1*S*, 2*S*)-**1b** (2.25 g, 15.95 mmol, 42% yield). (±)-*trans*-**1b** (4.00 g, 28.35 mmol) with Lipase AK gave (1*R*, 2*R*)-**2b** (2.30 g, 12.56 mmol, 44% yield) and (1*S*, 2*S*)-**1b** (1.60 g, 11.34 mmol, 40% yield). (±)-*trans*-**1b** (2.50 g, 17.72 mmol) with Lipase AY30 gave (1*R*, 2*R*)-**2b** (0.77 g, 4.21 mmol, 24% yield) and (1*S*, 2*S*)-**1b** (1.62 g, 11.48 mmol, 65% yield). (±)-*trans*-**1b** (2.50 g, 17.72 mmol) with Lipase AP12 gave (1*R*, 2*R*)-**2b** (0.24 g, 1.31 mmol, 7% yield) and (1*S*, 2*S*)-**1b** (1.94 g, 13.75 mmol, 78% yield). (±)-*trans*-**1c** (1.20 g, 7.74 mmol) with Lipase PS gave (1*R*, 2*R*)-**2c** (0.62 g, 3.15 mmol, 41% yield) and (1*S*, 2*S*)-**1c** (0.55 g, 3.55 mmol, 41% yield). (±)-*trans*-**1c** (14.00 g, 90.26 mmol) with Lipase AK gave (1*R*, 2*R*)-**2c** (7.94 g, 40.28 mmol, 45% yield) and (1*S*, 2*S*)-**1c** (5.78 g, 37.26 mmol, 41% yield). (±)-*trans*-**1c** (1.18 g, 7.61 mmol) with Lipase AY30 gave (1*R*, 2*R*)-**2c** (0.48 g, 2.44 mmol, 32% yield) and (1*S*, 2*S*)-**1c** (0.60 g, 3.87 mmol, 51% yield). (±)-*trans*-**1c** (1.30 g, 8.38 mmol) with Lipase AP12 gave (1*R*, 2*R*)-**2c** (0.08 g, 0.41 mmol, 5% yield) and (1*S*, 2*S*)-**1c** (1.03 g, 6.64 mmol, 79% yield). (±)-*cis*-**1a** (3.00 g, 23.61 mmol) with Lipase PS (4 hr reaction time) gave (1*R*, 2*S*)-**2a** (1.68 g, 9.94 mmol, 42% yield) and (1*S*, 2*R*)-**1a** (1.41 g, 11.10 mmol, 47% yield). (±)-*cis*-**1a** (0.70 g, 5.51 mmol) with Lipase PS (12 hr reaction time) gave (1*R*, 2*S*)-**2a** (0.46 g, 2.72 mmol, 49% yield) and (1*S*, 2*R*)-**1a** (0.25 g, 1.97 mmol, 36% yield). (±)-*cis*-**1a** (26.00 g, 204.60 mmol) with Lipase AK (6 hr reaction time) gave (1*R*, 2*S*)-**2a** (16.47 g, 97.42 mmol, 48% yield) and (1*S*, 2*R*)-**1a** (12.52 g, 98.53 mmol, 48% yield). (±)-*cis*-**1a** (0.67 g, 5.27 mmol) with Lipase AK (12 hr reaction time) gave (1*R*, 2*S*)-**2a** (0.43 g, 2.54 mmol, 48% yield) and (1*S*, 2*R*)-**1a** (0.29 g, 2.28 mmol, 43% yield). (±)-*cis*-**1b** (1.20 g, 8.51 mmol) with Lipase PS (10 hr reaction time) gave (1*R*, 2*S*)-**2b** (0.74 g, 4.04 mmol, 47% yield) and (1*S*, 2*R*)-**1b** (0.57 g, 4.04 mmol, 47% yield). (±)-*cis*-**1b** (1.70 g, 12.05 mmol) with Lipase AK (10 hr reaction time) gave (1*R*, 2*S*)-**2b** (1.04 g, 5.68 mmol, 47% yield) and (1*S*, 2*R*)-**1b** (0.82 g, 5.81 mmol, 48% yield).

*Determination of the enantiomeric excess (ee) and the absolute configuration of acetylated 2a~c and remaining substrates 1a~c.* *General method:* To a solution of NaOMe (20 mg) in MeOH (5 ml) was added (1*R*, 2*R*)-**2a** (0.82 g, 4.85 mmol), and the mixture was stirred for 1 hour at room temperature. The reaction mixture was washed with water to neutrality, extracted with CHCl<sub>3</sub>, dried with MgSO<sub>4</sub>, filtered, and concentrated *in vacuo*.

The residue was submitted to the next process. To a solution of  $\text{Ph}_3\text{P}$  (1.27 g, 4.84 mmol) in  $\text{THF-H}_2\text{O}$  (20 ml, 10:1, v/v) was added this residue. The reaction mixture was stirred for 12 hours at room temperature and then concentrated *in vacuo*. The residue obtained was chromatographed on silica gel. Elution with  $\text{CHCl}_3\text{-MeOH-Et}_3\text{N}$  (10:1:0.5) gave *trans*-2-amino cyclopentanol (1*R*, 2*R*)-**3a** (0.36 g, 3.56 mmol, 73% yield in two steps). (1*S*, 2*S*)-**3a** was prepared from (1*S*, 2*S*)-**1a** according to the procedures described for (1*R*, 2*R*)-**2a**, except for the deacetylation process. To a solution of WSC (20 mg, 0.10 mmol), DMAP (5 mg, 0.04 mmol), and (*S*)-TBMB carboxylic acid (50 mg, 0.21 mmol) in  $\text{CH}_2\text{Cl}_2$  (5 ml) was added (1*R*, 2*R*)-**3a** (10 mg, 0.10 mmol). The mixture was stirred for 14 hours at room temperature, and then concentrated *in vacuo*. After being purified by preparative TLC, the sample of (1*R*, 2*R*)-**5a** was submitted to the HPLC and CD analyses.

(1*R*, 2*R*)-*trans*-2-aminocyclopentanol [(1*R*, 2*R*)-**3a**]. (1*R*, 2*R*)-**3a** was purified by preparative TLC to give the enantiomerically pure form as an oil. Which solidified with time, mp 82–83°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.75 (m, 1H), 3.03 (m, 1H), 2.34 (s, 3H, -OH, -NH<sub>2</sub>), 2.00 (m, 2H), 1.70 (m, 2H), 1.54 (m, 1H), 1.19 (m, 1H). HRMS  $m/z$ : calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ , 101.0840 ( $\text{M}^+$ ); found, 102.0922 ( $\text{M}^+ + \text{H}$ ) (FAB<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = -30.59$  ( $c=0.78$  in MeOH). Anal. Calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ : C, 59.36; H, 10.97; N, 13.85%. Found: C, 59.39; H, 10.92; N, 13.79%.

(1*S*, 2*S*)-*trans*-2-aminocyclopentanol [(1*S*, 2*S*)-**3a**]. (1*S*, 2*S*)-**3a** was purified by preparative TLC to give the enantiomerically pure form as an oil which solidified with time, mp 82–83°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.75 (m, 1H), 3.02 (m, 1H), 2.60 (s, 3H, -OH, -NH<sub>2</sub>), 2.00 (m, 2H), 1.70 (m, 2H), 1.55 (m, 1H), 1.30 (m, 1H). HRMS  $m/z$ : calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ , 101.0840 ( $\text{M}^+$ ); found, 102.0923 ( $\text{M}^+ + \text{H}$ ) (FAB<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = +30.65$  ( $c=0.71$  in MeOH). Anal. Calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ : C, 59.36; H, 10.97; N, 13.85%. Found: C, 59.35; H, 10.94; N, 13.82%.

(1*R*, 2*R*)-*trans*-2-aminocyclohexanol [(1*R*, 2*R*)-**3b**]. (1*R*, 2*R*)-**3b** was recrystallized from ethyl acetate in a 76% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 87°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.10 (m, 1H), 2.40 (m, 1H), 2.17 (s, 3H, -OH, -NH<sub>2</sub>), 2.12–1.65 (m, 6H), 1.46–1.22 (m, 2H). HRMS  $m/z$ : calcd. for  $\text{C}_6\text{H}_{13}\text{ON}$ , 115.0996 ( $\text{M}^+$ ); found, 115.0997 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = -40.1$  ( $c=0.41$  in MeOH). Anal. Calcd. for  $\text{C}_6\text{H}_{13}\text{ON}$ : C, 62.55; H, 11.38; N, 12.17%. Found: C, 62.60; H, 11.31; N, 12.08%.

(1*S*, 2*S*)-*trans*-2-aminocyclohexanol [(1*S*, 2*S*)-**3b**]. (1*S*, 2*S*)-**3b** was recrystallized from ethyl acetate in a 72% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 87°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.12 (m, 1H), 2.40 (m, 1H), 2.17 (s, 3H, -OH, -NH<sub>2</sub>),

2.12–1.65 (m, 6H), 1.46–1.23 (m, 2H). HRMS  $m/z$ : calcd. for  $\text{C}_6\text{H}_{13}\text{ON}$ , 115.0996 ( $\text{M}^+$ ); found, 115.0997 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = +40.4$  ( $c=0.41$  in MeOH). Anal. Calcd. for  $\text{C}_6\text{H}_{13}\text{ON}$ : C, 62.55; H, 11.38; N, 12.17%. Found: C, 62.32; H, 11.33; N, 12.12%.

(1*R*, 2*R*)-*trans*-2-aminocycloheptanol [(1*R*, 2*R*)-**3c**]. (1*R*, 2*R*)-**3c** was recrystallized from ethyl acetate in a 78% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 93°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.18 (m, 1H), 2.49 (m, 1H), 2.11 (s, 3H, -OH, -NH<sub>2</sub>), 1.92 (m, 1H), 1.74 (m, 1H), 1.64 (m, 2H), 1.56–1.36 (m, 6H). HRMS  $m/z$ : calcd. for  $\text{C}_7\text{H}_{15}\text{ON}$ , 129.1153 ( $\text{M}^+$ ); found, 129.1156 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = -17.20$  ( $c=0.77$  in MeOH). Anal. Calcd. for  $\text{C}_7\text{H}_{15}\text{ON}$ : C, 65.06; H, 12.39; N, 10.85%. Found: C, 64.81; H, 12.26; N, 10.82%.

(1*S*, 2*S*)-*trans*-2-aminocycloheptanol [(1*S*, 2*S*)-**3c**]. (1*S*, 2*S*)-**3c** was recrystallized from ethyl acetate in a 76% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 93°C.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.18 (m, 1H), 2.49 (m, 1H), 2.11 (s, 3H, -OH, -NH<sub>2</sub>), 1.92 (m, 1H), 1.77 (m, 1H), 1.65 (m, 2H), 1.58–1.36 (m, 6H). HRMS  $m/z$ : calcd. for  $\text{C}_7\text{H}_{15}\text{ON}$ , 129.1153 ( $\text{M}^+$ ); found, 129.1155 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = +17.19$  ( $c=0.63$  in MeOH). Anal. Calcd. for  $\text{C}_7\text{H}_{15}\text{ON}$ : C, 65.06; H, 12.39; N, 10.85%. Found: C, 65.01; H, 12.36; N, 10.84%.

(1*R*, 2*S*)-*cis*-2-aminocyclopentanol [(1*R*, 2*S*)-**3a**]. (1*R*, 2*S*)-**3a** was recrystallized from ethyl acetate in a 78% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 74–76°C.  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.90 (m, 1H), 3.23 (m, 1H), 2.34 (s, 3H, -OH, -NH<sub>2</sub>), 1.84 (m, 3H), 1.71 (m, 1H), 1.53 (m, 1H), 1.43 (m, 1H). HRMS  $m/z$ : calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ , 101.0840 ( $\text{M}^+$ ); found, 101.0841 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = -15.56$  ( $c=0.36$  in MeOH). Anal. Calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ : C, 59.36; H, 10.97; N, 13.85%. Found: C, 59.29; H, 10.92; N, 13.81%.

(1*S*, 2*R*)-*cis*-2-aminocyclopentanol [(1*S*, 2*R*)-**3a**]. (1*S*, 2*R*)-**3a** was recrystallized from ethyl acetate in a 82% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 74–76°C.  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm): 3.90 (m, 1H), 3.23 (m, 1H), 2.34 (s, 3H, -OH, -NH<sub>2</sub>), 1.84 (m, 3H), 1.71 (m, 1H), 1.53 (m, 1H), 1.43 (m, 1H). HRMS  $m/z$ : calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ , 101.0840 ( $\text{M}^+$ ); found, 101.0839 ( $\text{M}^+$ ) (EI<sup>+</sup>).  $[\alpha]_{\text{D}}^{20} = +15.48$  ( $c=0.40$  in MeOH). Anal. Calcd. for  $\text{C}_5\text{H}_{11}\text{ON}$ : C, 59.36; H, 10.97; N, 13.85%. Found: C, 59.41; H, 10.91; N, 13.84%.

(1*R*, 2*S*)-*cis*-2-aminocyclohexanol [(1*R*, 2*S*)-**3b**]. (1*R*, 2*S*)-**3b** was recrystallized from ethyl acetate in a 79% yield. The enantiomeric excess was determined as

100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 73°C. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ (ppm): 3.69 (m, 1H), 2.90 (m, 1H), 1.84 (s, 3H, -OH, -NH<sub>2</sub>), 1.79 (m, 1H), 1.54 (m, 5H), 1.34 (m, 2H). HRMS *m/z*: calcd. for C<sub>6</sub>H<sub>13</sub>ON, 115.0996 (M<sup>+</sup>); found, 115.0997 (M<sup>+</sup>) (EI<sup>+</sup>). [α]<sub>D</sub><sup>20</sup> = -26.23 (c=0.41 in MeOH). *Anal.* Calcd. for C<sub>6</sub>H<sub>13</sub>ON: C, 62.55; H, 11.38; N, 12.17%. Found: C, 62.61; H, 11.42; N, 12.09%.

(*1S, 2R*)-*cis*-2-aminocyclohexanol [(*1S, 2R*)-**3b**]. (*1S, 2R*)-**3b** was recrystallized from ethyl acetate in a 74% yield. The enantiomeric excess was determined as 100% by an HPLC analysis, using (*S*)-TBMB carboxylic acid. mp 73°C. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ (ppm): 3.69 (m, 1H), 2.90 (m, 1H), 1.84 (s, 3H, -OH, -NH<sub>2</sub>), 1.79 (m, 1H), 1.54 (m, 5H), 1.34 (m, 2H). HRMS *m/z*: calcd. for C<sub>6</sub>H<sub>13</sub>ON, 115.0996 (M<sup>+</sup>); found, 115.0999 (M<sup>+</sup>) (EI<sup>+</sup>). [α]<sub>D</sub><sup>20</sup> = +26.30 (c=0.38 in MeOH). *Anal.* Calcd. for C<sub>6</sub>H<sub>13</sub>ON: C, 62.55; H, 11.38; N, 12.17%. Found: C, 62.51; H, 11.42; N, 12.16%.

## Acknowledgment

We are grateful to Amano Pharmaceutical Co. Ltd. for generously presenting the lipases.

## References

- 1) Pecunioso, A., Maffei, M., Marchioro, C., Rossi, L., and Tamburini, B., Synthesis and enantiomeric excess determination of (6*S*)-1-(trimethylsilyloxy)-6-(*N*-methyl-*N*-benzyloxycarbonyl-amino)-cyclohexene. *Tetrahedron: Asymmetry*, **8**, 775 (1997).
- 2) Overman, L. E., Mendelson, L. T., and Jacobsen, E. J., Applications of cationic Aza-Cope rearrangements for alkaloid synthesis. Stereoselective preparation of *cis*-3a-aryloctahydroindoles and a new short route to amaryllidaceae alkaloids. *J. Am. Chem. Soc.*, **105**, 6629-6637 (1983).
- 3) Merck's HIV protease inhibitor, Crixivan®, which is one of the most promising drugs for treating the acquired immuno-deficiency syndrome (AIDS), contains a *cis*-1-amino-2-indanol skeleton. See Senanayake, C. H., Applications of *cis*-1-amino-2-indanol in asymmetric synthesis. *Aldrichimica Acta*, **31**, 3-15 (1998).
- 4) Nohira, H., Optical resolution of organic compounds by means of crystallization. *Nippon Kagaku Kaishi* (in Japanese), 915-920 (1989).
- 5) a) Saigo, K., Sudo, A., and Hashimoto, Y., Asymmetric reactions using non-natural chiral auxiliaries. *J. Synth. Org. Chem. Jpn.* (in Japanese), **56**, 386-394 (1998); b) For a synthesis of acyclic 2-amino alkanols as chiral auxiliaries, see Ishizuka, T., Synthetic 2-amino alcohol derivatives as chiral auxiliaries. *Yakugaku Zasshi* (in Japanese), **117**, 339-352 (1997).
- 6) Many attempts have been made to obtain enantiomerically pure *trans*-2-aminocycloalkanol (including the precursors, *trans*-2-azidocycloalkanol); a) For the preparation of *trans*-2-aminocyclopentanol, see Barr, A. A., Frenkel, I., and Robinson, B., The preparation and absolute configuration of *trans*-2-aminocyclopentanol enantiomers. *Can. J. Chem.*, **55**, 4180-4183 (1977); b) For the preparation of *trans*-2-azidocycloalkanol derivatives, see Nugent, W. A., Chiral Lewis acid catalysis. Enantioselective addition of azide to meso epoxides. *J. Am. Chem. Soc.*, **114**, 2768-2769 (1992); c) Nugent, W. A., Desymmetrization of meso epoxides with halides: a new catalytic reaction based on mechanistic insight. *J. Am. Chem. Soc.*, **120**, 7139-7140 (1998); d) Martinez, L. E., Leighton, J. L., Carsten, D. H., and Jacobsen, E. N., Highly enantioselective ring opening of epoxides catalyzed by (salen)Cr(III) complexes. *J. Am. Chem. Soc.*, **117**, 5897-5898 (1995); e) For *cis*-2-aminocycloalkanol, see Laukhten, G., Volk, F.-J., Frahm, A. W., Diastereo- and enantioselective synthesis of *cis*-2-hydroxycyclohexanamine and corresponding ethers by asymmetric reductive amination. *Tetrahedron: Asymmetry*, **8**, 3457-3466 (1997).
- 7) Overman, L. E. and Sugai, S., A convenient method for obtaining *trans*-2-aminocyclohexanol and *trans*-2-aminocyclopentanol in enantiomerically pure form. *J. Org. Chem.*, **50**, 4154-4155 (1985).
- 8) Recent reviews, see a) Schoffers, E., Golebiowski, A., and Johnson, C. R., Enantioselective synthesis through enzymatic asymmetrization. *Tetrahedron*, **52**, 3769-3826 (1996); b) Roberts, S. M., Preparative biotransformations: the employment of enzymes and whole-cells in synthetic organic chemistry. *J. Chem. Soc. Perkin Trans. 1*, 157-169 (1998).
- 9) Shimizu, T., Hiranuma, S., and Nakata, T., Efficient method for inversion of secondary alcohols by reaction of chloromethanesulfonates with cesium acetate. *Tetrahedron Lett.*, **37**, 6145-6148 (1996).
- 10) Hassener, A. and Stumer, C., Organic syntheses based on name reactions and unnamed reactions, Elsevier Science Ltd, U.K., pp. 359 (1994).
- 11) (*S*)-TBMB carboxylic acid has strong fluorescence [*E*<sub>x</sub>, 310 nm, *E*<sub>m</sub>, 380 nm] and could be conveniently applied to an enantiomeric analysis based on fluorescence-monitored HPLC. For the preparation, see Nishida, Y., Itoh, E., Abe, M., Ohroi, H., and Meguro, H., Syntheses of a series of fluorescent carboxylic acids with a 1,3-benzodioxole skeleton and their evaluation as chiral derivatizing reagents. *Anal. Sci.*, **11**, 213-220 (1995).
- 12) These molecular designs are based on the new concept that the remote-asymmetric centers could be recognized by the CH/π interaction. a) For details, see Ohroi, H., Strategies for development of fluorescent derivatization reagents for highly sensitive analysis of biomolecules. *J. Synth. Org. Chem. Jpn.* (in Japanese), **56**, 591-603 (1998); b) For the CH/π interaction, see Nishino, M., Umezawa, Y., and Hirota, M., The CH/π interaction. Implications in molecular recognition. *J. Synth. Org. Chem. Jpn.* (in Japanese), **55**, 2-12 (1997).